Health Catalyst (NASDAQ:HCAT) Trading Up 8% After Analyst Upgrade

Health Catalyst, Inc. (NASDAQ:HCAT)’s stock price shot up 8% on Wednesday after Citigroup raised their price target on the stock from $9.00 to $10.50. Citigroup currently has a buy rating on the stock. Health Catalyst traded as high as $8.83 and last traded at $8.78. 84,323 shares traded hands during trading, a decline of 85% from the average session volume of 561,146 shares. The stock had previously closed at $8.13.

HCAT has been the subject of a number of other reports. JPMorgan Chase & Co. increased their target price on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a report on Wednesday, September 4th. Evercore ISI increased their price objective on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. Piper Sandler reduced their target price on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, August 26th. Stephens dropped their price target on Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating for the company in a research note on Thursday, August 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a report on Friday, October 4th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $11.54.

Insider Activity

In related news, COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $7.70, for a total value of $40,109.30. Following the completion of the transaction, the chief operating officer now owns 129,690 shares in the company, valued at approximately $998,613. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, COO Daniel Lesueur sold 5,209 shares of the stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $7.70, for a total value of $40,109.30. Following the sale, the chief operating officer now directly owns 129,690 shares of the company’s stock, valued at $998,613. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total value of $54,150.00. Following the completion of the sale, the insider now owns 255,881 shares in the company, valued at approximately $1,847,460.82. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 34,068 shares of company stock worth $257,555. 2.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Health Catalyst

Several hedge funds have recently made changes to their positions in the company. First Light Asset Management LLC lifted its position in shares of Health Catalyst by 438.5% in the 2nd quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock worth $25,279,000 after purchasing an additional 3,221,408 shares during the period. Impax Asset Management Group plc lifted its holdings in Health Catalyst by 16.4% during the third quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock worth $20,793,000 after buying an additional 360,201 shares during the period. Millennium Management LLC lifted its holdings in Health Catalyst by 96.3% during the second quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock worth $15,421,000 after buying an additional 1,184,131 shares during the period. Primecap Management Co. CA boosted its position in Health Catalyst by 1.1% during the 3rd quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company’s stock valued at $19,572,000 after acquiring an additional 25,000 shares in the last quarter. Finally, Daventry Group LP increased its holdings in shares of Health Catalyst by 3.9% in the 2nd quarter. Daventry Group LP now owns 2,247,053 shares of the company’s stock valued at $14,359,000 after acquiring an additional 84,178 shares during the period. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Health Catalyst Trading Up 6.5 %

The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $526.96 million, a P/E ratio of -6.55 and a beta of 1.32. The company has a 50-day moving average price of $8.11 and a 200 day moving average price of $7.19.

Health Catalyst (NASDAQ:HCAT) last announced its earnings results on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The firm had revenue of $76.40 million during the quarter, compared to the consensus estimate of $76.27 million. During the same quarter in the prior year, the firm posted ($0.22) earnings per share. The business’s revenue for the quarter was up 3.5% compared to the same quarter last year. On average, research analysts forecast that Health Catalyst, Inc. will post -0.35 earnings per share for the current fiscal year.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.